Diabetic Nephropathy: Clinical Trials

22 trials for Diabetic Nephropathy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

17 completed, 4 terminated, 1 not yet recruiting. 22 Phase 3, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 322Completed 17, Terminated 4, Not yet recruiting 1
Phase 24Completed 4

Follow Diabetic Nephropathy: new trials by email Literature Review of Diabetic Nephropathy trials Research Report on Diabetic Nephropathy

Trials (filtered) newest first · largest first

All 22 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
"Dapagliflozin vs Dapagliflozin-Finerenone for Albuminuria in CKD With Type 2 Diabetes"
Dapagliflozin +Finerenone arm, Dapagliflozin arm - Diabetic Nephropathy
Phase 3Not yet recruitingChittagong Medical College882026-05-012026-05-20
Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy
Canagliflozin, Placebo - Diabetic Nephropathy
Phase 3CompletedTanabe Pharma Corporation3082018-02-152026-01-07
Effect of Pirfenidone on Glomerular Filtration Rate and Albuminuria in Patients With Diabetic Nephropathy
Pirfenidone, Placebo - Diabetic Nephropathy, Albuminuria
Phase 3CompletedInstituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran622016-03-012023-03-14
Pyridorin in Diabetic Nephropathy
Pyridorin, Placebo - Diabetic Nephropathy, Diabetic Kidney Disease
Phase 3TerminatedNephroGenex, Inc.3282014-06-012016-03-09
Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria
Spironolactone, Placebo, Standard care - Diabetic Nephropathy, Diabetic Retinopathy
Phase 2 / Phase 3CompletedPeter Rossing17772014-03-012018-12-21
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy
Canagliflozin, Placebo - Diabetes Mellitus, Type 2, Diabetic Nephropathy
Phase 3CompletedJanssen Research & Development, LLC44012014-02-172019-12-05
Study Of Diabetic Nephropathy With Atrasentan
Atrasentan, Placebo - Diabetic Nephropathy
Phase 3TerminatedAbbVie51072013-05-172019-04-24
Open Label Tolerability and Safety Study of KRX-101 in Australia, New Zealand, and Hong Kong
sulodexide - Diabetic Nephropathy
Phase 3TerminatedKeryx Biopharmaceuticals2002007-04-012017-03-03
Efficacy of Telmisartan and the Combination of Telmisartan and Ramipril in type1 Diabetes Patients With Nephropathy
Telmisartan, Ramipril - Diabetic Nephropathy
Phase 3CompletedPost Graduate Institute of Medical Education and Research, Chandigarh302007-02-012008-08-20
Efficacy of N-Acetylcysteine in Treatment of Overt Diabetic Nephropathy
N-acetylcysteine - Diabetic Nephropathy, Chronic Kidney Disease
Phase 2 / Phase 3CompletedShiraz University of Medical Sciences602007-01-012007-11-12
Assessment of the Effect of Captopril Versus Combination of Captopril and Pentoxifylline on Reducing Proteinuria in Type 2 Diabetic Nephropathy
Captopril, Captopril + Pentoxifylline - Diabetic Nephropathy
Phase 2 / Phase 3CompletedShiraz University of Medical Sciences702006-02-012008-04-22
Effect of Sulodexide in Early Diabetic Nephropathy
Sulodexide, Placebo - Diabetic Nephropathy
Phase 3CompletedKeryx Biopharmaceuticals10562005-08-012018-03-23
To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy
SPP301 - Diabetic Nephropathy
Phase 3TerminatedSpeedel Pharma Ltd.23642005-07-012007-10-05
Role of Sleep Apnea and Sympathetic Activity in Resistant Hypertensive Patients.
NCPAP; Nasal continuous positive airway pressure., NCPAP Nasal Continuous Positive Airway Pressure-sub-therapeutic treatment group - Type 2 Diabetes, Diabetic Nephropathy
Phase 3CompletedOttawa Hospital Research Institute162004-12-012015-02-10
Evaluation Study for the Programme DiaNe for People With Diabetic Nephropathy
DiaNe consultation and support program - Diabetic Nephropathy
Phase 3CompletedDiaNe HCM GmbH1252004-07-012008-10-31
Olmesartan Medoxomil and Diabetic Nephropathy
Olmesartan medoxomil, Losartan - Type 2 Diabetes Mellitus, Diabetic Nephropathy
Phase 3CompletedSankyo Pharma Gmbh3002003-05-012006-10-09
ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial
olmesartan medoxomil, Placebo Tablets - Diabetic Nephropathy, Type 2 Diabetes Mellitus
Phase 3CompletedDaiichi Sankyo Co., Ltd.5772003-04-012011-05-10
European Trial of Immunosuppression in SPK Tx
sirolimus versus mycophenolate mofetil - Diabetes Mellitus, Type 1, Diabetic Nephropathy
Phase 3CompletedEUROSPK Study Group2282002-02-012021-08-23
Using the Drug Spironolactone to Test If It Reduces Protein Leakage From the Kidney
Spironolactone, Irbesartan - Kidney Disease, Diabetic Nephropathy
Phase 2 / Phase 3CompletedMelbourne Health602002-01-012005-06-24
Renoprotection in Early Diabetic Nephropathy in Pima Indians
Losartan, Placebo - Diabetic Nephropathy
Phase 3CompletedNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)1701995-08-012021-03-25

Showing 20 of 22. Sign in to see all of them.

Narrower conditions

Diabetic Nephropathies (22)  ·  Diabetes Mellitus, Type 2 (9)  ·  Diabetes Mellitus (6)  ·  Kidney Diseases (6)  ·  Proteinuria (6)  ·  Albuminuria (3)  ·  Kidney Failure, Chronic (3)  ·  Renal Insufficiency, Chronic (3)  ·  Diabetic Retinopathy (2)  ·  Hypertension (2)  ·  Diabetes Mellitus, Type 1 (1)  ·  Diabetic Neuropathies (1)  ·  Glomerulonephritis (1)  ·  Rare Diseases (1)  ·  Renal Insufficiency (1)

Broader conditions

Diabetes Complications (22)  ·  Endocrine System Diseases (22)  ·  Female Urogenital Diseases (22)  ·  Female Urogenital Diseases and Pregnancy Complications (22)  ·  Male Urogenital Diseases (22)  ·  Urologic Diseases (22)  ·  Urogenital Diseases (21)  ·  Diabetes Mellitus (16)  ·  Kidney Diseases (16)  ·  Glucose Metabolism Disorders (15)  ·  Metabolic Diseases (15)  ·  Nutritional and Metabolic Diseases (15)  ·  Pathological Conditions, Signs and Symptoms (12)  ·  Signs and Symptoms (8)  ·  Urination Disorders (8)

Interventions

Canagliflozin (2)  ·  Losartan (2)  ·  Olmesartan Medoxomil (2)  ·  Spironolactone (2)  ·  glucuronyl glucosamine glycan sulfate (2)  ·  Acetylcysteine (1)  ·  Atrasentan (1)  ·  Avosentan (1)  ·  Captopril (1)  ·  Continuous Positive Airway Pressure (1)  ·  Irbesartan (1)  ·  Lisinopril (1)  ·  Nifedipine (1)  ·  Pentoxifylline (1)  ·  Ramipril (1)

Sponsors

Keryx Biopharmaceuticals (2)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2)  ·  Shiraz University of Medical Sciences (2)  ·  AbbVie (1)  ·  Chittagong Medical College (1)  ·  Daiichi Sankyo Co., Ltd. (1)  ·  DiaNe HCM GmbH (1)  ·  EUROSPK Study Group (1)  ·  Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran (1)  ·  Janssen Research & Development, LLC (1)  ·  Joslin Diabetes Center (1)  ·  Melbourne Health (1)  ·  NephroGenex, Inc. (1)  ·  Ottawa Hospital Research Institute (1)  ·  Peter Rossing (1)

Countries

United States (7)  ·  Germany (6)  ·  Australia (5)  ·  Spain (5)  ·  Czechia (4)  ·  Japan (3)  ·  Netherlands (3)  ·  Poland (3)  ·  Belgium (2)  ·  Bulgaria (2)  ·  Canada (2)  ·  China (2)  ·  France (2)  ·  Hungary (2)  ·  India (2)

Top investigators

Adriaan Kooy, MD (1)  ·  Alberto Ortiz, MD (1)  ·  Amin Banihashemi (1)  ·  Andreas Birkenfeld, MD (1)  ·  Anne Reutens, MD (1)  ·  Bertram L. Kasiske (1)  ·  Christian Delles, MD (1)  ·  Edmund J Lewis, M.D. (1)  ·  Gavin G Becker, MBBS MD (1)  ·  Gerjan Navis, MD (1)  ·  Goce Spasovski, MD (1)

Results publications

PMID 33107592, PMID 37872654, PMID 38682786, PMID 38770818, PMID 40526444, PMID 20189608, PMID 21872376, PMID 21993710, PMID 22718189, PMID 23545707, PMID 24013685, PMID 26936907, PMID 27612501, PMID 29253846, PMID 29781558, PMID 30990260, PMID 30995972, PMID 31291786, PMID 31573977, PMID 31707795, PMID 32135136, PMID 32354987, PMID 32930969, PMID 33263893, PMID 33338269, PMID 33340064, PMID 33358942, PMID 33554616, PMID 33619120, PMID 33826709, PMID 33874750, PMID 34027894, PMID 34029680, PMID 34437304, PMID 34853062, PMID 35063969, PMID 35772861, PMID 35861630, PMID 35929472, PMID 35938182, PMID 36302584, PMID 36841085, PMID 36889425, PMID 36999981, PMID 37120538, PMID 37345834, PMID 37438734, PMID 37603600, PMID 37657768, PMID 37671609

NIH funding

2005 (1), 2014 (1), R01DK047112 (1)